Drug intelligence / Profile preview

CSAC

Development stage: Unknown
Lead developer: Universidade do Vale do Sapucaí
Modality: Small Molecules
Administration: Topical

Overview

CSAC is a surgical antisepsis protocol consisting of a two-step application of chlorhexidine: first as a chlorhexidine-based soap and then as an alcohol-based chlorhexidine solution. It is used for preoperative skin preparation to prevent bacterial colonization and surgical site infections (SSI), particularly in orthopedic procedures. The protocol was evaluated in a randomized clinical trial by the Universidade do Vale do Sapucaí in Brazil, where it was compared to a three-step protocol (CSAAC) that included an intermediate 70% ethyl alcohol step. Chlorhexidine acts as an antiseptic by targeting bacterial cell membranes, leading to the disruption of microbial integrity and cell death.

Other names: chlorhexidine-based soap + alcohol-based chlorhexidine

Beyond the preview

Go deeper on CSAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSAC.

Explore the full profile